CHO-K1/Human CB1 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0048A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The cannabinoid receptor 1 (CB1), encoded by the CNR1 gene, is a predominant G protein-coupled receptor within the endocannabinoid system. It is highly concentrated in the central nervous system, particularly in brain regions such as the basal ganglia, hippocampus, cerebellum, and cortex. By modulating neurotransmitter release, CB1 critically regulates a wide array of physiological processes including pain perception, appetite, mood, memory, and motor coordination. Its dysfunction is implicated in various disorders, making it a pivotal therapeutic target for conditions like neuropathic pain, epilepsy, anxiety, schizophrenia, and obesity. Pharmacological agents targeting CB1, including agonists and antagonists, hold significant potential for treating these neuropsychiatric and metabolic diseases.
Screeningbio’s CHO-K1/Human CB1 cell line overexpress CNR1 and is designed to detect decreases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | CNR1 |
Accession Number | NM_016083 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The cannabinoid receptor 1 (CB1), encoded by the CNR1 gene, is a predominant G protein-coupled receptor within the endocannabinoid system. It is highly concentrated in the central nervous system, particularly in brain regions such as the basal ganglia, hippocampus, cerebellum, and cortex.
By modulating neurotransmitter release, CB1 critically regulates a wide array of physiological processes including pain perception, appetite, mood, memory, and motor coordination.
Its dysfunction is implicated in various disorders, making it a pivotal therapeutic target for conditions like neuropathic pain, epilepsy, anxiety, schizophrenia, and obesity. Pharmacological agents targeting CB1, including agonists and antagonists, hold significant potential for treating these neuropsychiatric and metabolic diseases.